BR112021021262A2 - Formulação de mrna - Google Patents

Formulação de mrna

Info

Publication number
BR112021021262A2
BR112021021262A2 BR112021021262A BR112021021262A BR112021021262A2 BR 112021021262 A2 BR112021021262 A2 BR 112021021262A2 BR 112021021262 A BR112021021262 A BR 112021021262A BR 112021021262 A BR112021021262 A BR 112021021262A BR 112021021262 A2 BR112021021262 A2 BR 112021021262A2
Authority
BR
Brazil
Prior art keywords
mrna
present
mrna molecules
combinations
formulation
Prior art date
Application number
BR112021021262A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Tomme
Sanne Bevers
De Koker Stefaan
Original Assignee
Etherna Immunotherapies Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Etherna Immunotherapies Nv filed Critical Etherna Immunotherapies Nv
Publication of BR112021021262A2 publication Critical patent/BR112021021262A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021021262A 2019-04-26 2020-04-24 Formulação de mrna BR112021021262A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19171323 2019-04-26
PCT/EP2020/061477 WO2020216911A1 (en) 2019-04-26 2020-04-24 Mrna formulation

Publications (1)

Publication Number Publication Date
BR112021021262A2 true BR112021021262A2 (pt) 2021-12-21

Family

ID=66290283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021262A BR112021021262A2 (pt) 2019-04-26 2020-04-24 Formulação de mrna

Country Status (12)

Country Link
US (1) US20220362360A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958893A1 (cg-RX-API-DMAC7.html)
JP (1) JP7650001B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220023340A (cg-RX-API-DMAC7.html)
CN (1) CN114096272B (cg-RX-API-DMAC7.html)
AU (1) AU2020263948B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021262A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138011A1 (cg-RX-API-DMAC7.html)
IL (1) IL287560B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021013018A (cg-RX-API-DMAC7.html)
SG (1) SG11202111720TA (cg-RX-API-DMAC7.html)
WO (1) WO2020216911A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496623B2 (ja) * 2019-01-04 2024-06-07 イーザアールエヌーエー イムノセラピーズ エンヴェー mRNAワクチン
US20220143161A1 (en) * 2019-03-13 2022-05-12 Etherna Immunotherapies Nv Mrna vaccine
CN119701015A (zh) * 2023-09-26 2025-03-28 深圳瑞吉生物科技有限公司 一种细胞因子mRNA组合药物及其应用
CN121873266A (zh) * 2026-03-18 2026-04-17 北京悦康科创医药科技股份有限公司 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2201100E (pt) * 2007-09-14 2016-06-03 Univ Brussel Vrije Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US9408909B2 (en) * 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
EP3173474A1 (en) * 2007-09-14 2017-05-31 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2015071295A1 (en) 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
DK4276189T3 (da) * 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes

Also Published As

Publication number Publication date
SG11202111720TA (en) 2021-11-29
AU2020263948B2 (en) 2026-06-25
CN114096272B (zh) 2024-08-06
EP3958893A1 (en) 2022-03-02
CN114096272A (zh) 2022-02-25
WO2020216911A1 (en) 2020-10-29
JP7650001B2 (ja) 2025-03-24
IL287560B2 (en) 2026-02-01
US20220362360A1 (en) 2022-11-17
AU2020263948A1 (en) 2021-12-23
MX2021013018A (es) 2022-03-11
CA3138011A1 (en) 2020-10-29
IL287560B1 (en) 2025-10-01
JP2022532038A (ja) 2022-07-13
KR20220023340A (ko) 2022-03-02
IL287560A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
ZA202501799B (en) Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
MX2026002469A (es) Nuevas moleculas de acido nucleico artificiales
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
CO6341566A2 (es) Mutantes fgf21 y usos de de los mismos
AR113142A1 (es) Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
UY38740A (es) Mutantes de fgf21 y usos del mismo
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
WO2020252397A8 (en) Small molecule proteolysis-targeting chimeras and methods of use thereof
BR112023020219A2 (pt) Anticorpos anti-il-2r agonistas e métodos de uso
BR112022025250A2 (pt) Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, métodos para produzir uma molécula e induzir a lise de uma célula, composição farmacêutica, uso da molécula, métodos de tratamento de uma doença e invenção
BR112022020629A2 (pt) Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
BR112017026292A2 (pt) muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico
BR112017015773A2 (pt) muteína de lipocalina, muteína de hngal, molécula de ácido nucleico, célula hospedeira, método para produzir a muteína de hngal, composição farmacêutica, kit, uso da muteína de hngal, uso da muteína de hngal, método para ligar ang-2 em um indivíduo, método para inibir angiogênese em um indivíduo, método para tratar, prevenir ou melhorar uma doença e método para inibir ou reduzir angiogênese em um indivíduo
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
MA32771B1 (fr) Mutants fgf21 et leurs utilisations
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
MX2021013018A (es) Formulacion de arnm.
BR112021019070A2 (pt) Ligantes de pseudoquinase tyk2
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
BR112021015616A2 (pt) Ligantes de pseudoquinase tyk2
BR112015009954A2 (pt) Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VRIJE UNIVERSITEIT BRUSSEL (BE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ETHERNA IMMUNOTHERAPIES NV (BE)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2761 DE 05/12/2023 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: ETHERNA IMMUNOTHERAPIES NV (BE) ; VRIJE UNIVERSITEIT BRUSSEL (BE)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]